| Autor: |
Hsu RK; AIDS Healthcare Foundation, New York, New York, USA.; NYU Langone Medical Center, New York, New York, USA., Brunet L; Epividian, Inc., Durham, North Carolina, USA., Fusco JS; Epividian, Inc., Durham, North Carolina, USA., Mounzer K; Philadelphia FIGHT, Philadelphia, Pennsylvania, USA., Lamori JC; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA., Fusco GP; Epividian, Inc., Durham, North Carolina, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
AIDS research and human retroviruses [AIDS Res Hum Retroviruses] 2022 Oct; Vol. 38 (10), pp. 782-791. Date of Electronic Publication: 2022 Sep 01. |
| DOI: |
10.1089/AID.2021.0188 |
| Abstrakt: |
An observational cohort study was conducted with data from the Observational Pharmaco-Epidemiology Research & Analysis (OPERA) cohort to investigate weight gain among virologically suppressed people with HIV (PWH) switching to regimens containing tenofovir alafenamide/emtricitabine/(TAF/FTC). Virologically suppressed, antiretroviral therapy (ART)-experienced PWH switching to TAF/FTC with darunavir/cobicistat (DRV/c), elvitegravir/cobicistat (EVG/c), dolutegravir (DTG), or bictegravir (BIC) were selected. Cox proportional hazards models were used to assess the risk of excessive weight gain (i.e., ≥5% gain within 28 weeks or ≥10% within 54 weeks), by regimen. A linear mixed effects model with random intercept and restricted cubic splines on time was used to assess continuous changes in weight. Confounding was controlled for with both inverse probability of treatment weighting and traditional covariate adjustment. Among 5,536 PWH, 18% gained ≥5% of their weight within 28 weeks, and 9% gained ≥10% within 54 weeks. There were no differences in the risk of excessive weight gain by regimen, although there was a nonstatistically significant 20% increase in the risk of gaining ≥10% within 54 weeks with all regimens compared to DRV/c. Throughout follow-up, the mean predicted weight remained fairly constant, with no notable differentiation between regimens. Expected weight gains ranged from +0.2 to +0.3 kg at 6 months and from +0.5 to +0.6 kg at 24 months. In conclusion, in this study of virologically suppressed, ART-experienced PWH switching to regimens containing TAF/FTC and DRV/c, EVG/c, DTG, or BIC, up to 18% experienced excessive levels of weight gain. However, no statistically significant difference was observed across regimens. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
